GT Biopharma Inc GTBP 深 滬
等待開盤 01-28 09:30:00 美东时间
0.7394
+0.049
+7.16%
華盛通- 最 高0.74
- 今 開0.706
- 成交量 59.17万股
- 最 低 0.6901
- 昨 收 0.69
- 總市值 786.43万
- 52周最高 3.85
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 0.54
- 委 比 -78.57%
- 總股本 1063.61万
- 歷史最高 591.99
- 量 比 0.84
- 振 幅 7.23%
- 歷史最低 0.54
- 每 手 1
- 風險率 0.85%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/ -- Equity Insider News Commentary – The precision medicine sector is undergoing a structural realignment towa...
01-16 21:00
EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment
GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026.
01-15 21:01
EXCLUSIVE: GT Biopharma Announces IND Submission For GTB-5550 TriKE; Reports Preliminary Unaudited Cash Balance Of ~$7M As Of Dec. 31, 2025
GT Biopharma targets a portion of the estimated $362 billion global solid tumor market with its B7-H3 TrikePreliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extendGT Biopharma targets a portion of the estimated $362 billion global solid tumor market with its B7-H3 Trike
01-15 21:00
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
GT Biopharma submitted an IND application for GTB-5550, a B7-H3-targeted NK cell engager, to treat B7-H3-expressing solid tumors. The company aims to initiate a Phase 1 basket trial in 2026. GTB-5550 uses a TriKE platform combining anti-CD16, WT IL-15, and anti-B7-H3 nanobodies to activate NK cells. The trial will assess safety and tolerability across seven cancer types, with subcutaneous dosing over five days per week. The global market for B7-H...
01-15 13:30
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- Equity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has...
2025-12-19 20:55
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift to...
2025-12-11 23:17
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers GT Biopharma (NASDAQ:GTBP) shares moved upwards by 6.6% to $0.65 durin...
2025-12-06 05:05
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia ...
2025-12-05 01:20
Why Quantum Computing Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
Shares of Quantum Computing Inc. (NASDAQ:QUBT) rose sharply in pre-market tradi...
2025-11-17 17:42
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GT Biopharma announced updates on its Phase 1 trial for GTB-3650, targeting relapsed/refractory CD33+ hematologic malignancies, with enrollment ongoing and the next update expected in Q1 2026. The IND submission for GTB-5550, targeting B7H3+ solid tumors, is anticipated in late December 2025 or January 2026. The company reported a cash position of $2.6 million as of September 30, 2025, sufficient to fund operations into Q1 2026. R&D expenses decr...
2025-11-14 14:00
